Business Context and Reporting Period
Company: iSpecimen Inc. (ISPC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: iSpecimen operates a proprietary online marketplace connecting medical researchers with hospitals and laboratories to procure biospecimens (human biofluids, tissues, and cells). The company operates as a single reporting segment focused on the Americas, Europe, Middle East/Africa, and Asia Pacific.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 | Balance Sheet (Sept 30, 2025) |
|---|---|---|---|
| Revenue | $106,592 | $1,877,237 | N/A |
| Net Loss | $(2,780,648) | $(5,486,287) | N/A |
| Loss Per Share (Basic/Diluted) | $(0.48) | $(1.54) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $2,782,758 |
| Working Capital | N/A | N/A | $(2,096,503) |
| Total Assets | N/A | N/A | $8,997,557 |
| Total Liabilities | N/A | N/A | $5,924,846 |
| Accumulated Deficit | N/A | N/A | $(77,348,904) |
Cash Flow (Nine Months Ended Sept 30, 2025):
- Operating Activities: $(3,323,685)
- Investing Activities: $(1,000,454) (Primarily capitalization of internally developed software)
- Financing Activities: $5,228,489 (Proceeds from underwritten and private placement offerings)
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 96% quarter-over-quarter (Q3 2025 vs. Q3 2024) and 76% year-to-date. This is primarily attributed to a change in revenue recognition policy in Q4 2024 (shifting from "accessioned" to "delivered" specimens) and a significant drop in specimen volume (97% decrease in Q3).
- Expense Reduction: Total operating expenses decreased 33% in Q3 and 44% YTD compared to the prior year periods. This reflects aggressive cost-cutting measures, including workforce reductions that lowered monthly compensation costs by approximately 76% and technology costs by 69% YTD.
- Net Loss: Net loss increased 93% in Q3 due to the revenue collapse, though the YTD net loss decreased 15% due to significant expense reductions.
- Capitalization: The company capitalized $1,000,000 in internally developed software costs during the nine months ended Sept 30, 2025, compared to $588,000 in the prior year period, as part of a digital transformation program.
Guidance, Outlook, Risks, and Contingencies
Going Concern: The filing explicitly states that conditions raise substantial doubt regarding the company's ability to continue as a going concern for one year from the filing date. The company has a negative working capital of approximately $2.1 million and an accumulated deficit of $77.3 million. Management's plan relies on generating additional revenue and raising further capital, but success is not assured.
Capital Raising: During the nine months ended Sept 30, 2025, the company raised approximately $5.75 million in gross proceeds through an underwritten public offering and a private placement (PIPE) to fund operations.
Legal Proceedings:
- Focus Technology Solutions: A dispute regarding non-payment of IT services ($489,572 claimed) resulted in a temporary shutdown of the marketplace. A settlement of $500,000 was agreed upon, but the vendor failed to fully restore services. The court has ordered the company to deposit 15% of revenue into a dedicated account up to $420,000 as pre-judgment security.
- Azenta US, Inc.: Claiming $651,262 for breach of contract; currently in discovery.
- EGS: Claiming $425,684; settlement discussions are ongoing.
- Former CIO Arbitration: Settled for $215,000 in January 2025.
Internal Controls: The company identified a material weakness in internal controls over financial reporting related to the calculation, collection, and remittance of sales tax. The company has not historically collected sales tax from customers believed to be exempt, leading to a liability of approximately $272,000 plus penalties as of Sept 30, 2025.
Investor Verification Checklist
- Liquidity Runway: Verify if the $2.78 million cash balance is sufficient to cover the negative working capital and ongoing operating losses given the "substantial doubt" disclosure.
- Revenue Recognition Impact: Confirm the long-term impact of the Q4 2024 change in revenue recognition (from accessioned to delivered) on future reported revenue trends.
- Legal Exposure: Monitor the status of the Focus Technology Solutions litigation, specifically the requirement to deposit 15% of revenue into a restricted account and the potential for counterclaims.
- Sales Tax Liability: Track the remediation of the sales tax material weakness and the actual collection of the estimated $272,000 liability from customers.
- Capital Requirements: Assess the likelihood and terms of future equity financing required to sustain operations, given the history of recurring losses and the recent dilution from the 1-for-20 reverse stock split and subsequent offerings.